MRNA Past Earnings Q&A
What was the best and worst MRNA past earnings results?
For Moderna, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?
The highest MRNA past earnings result in our data set was 11.290/share posted in Q4 2021, while the lowest was in Q2 2023 when MRNA posted -3.620/share.
The biggest top line earnings performance — aka revenue — quarter was in Q4 2021 when MRNA reported 7.21B in revenue, while the quarter with the lowest revenue in our data set was Q1 2020 at 0.01B of revenue.
There are 19 MRNA past earnings results in our data set.
On this page we presented the MRNA past earnings date information for Moderna. Reviewing that
Moderna Past Earnings
for the company, we see that the highest past earnings result in our data set was in Q4 2021, when MRNA posted gaap of 11.290/share. Meanwhile the lowest MRNA past earnings result was in Q2 2023, when MRNA posted gaap of -3.620/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q4 2021 when MRNA reported 7.21B in revenue, while the smallest revenue quarter was Q1 2020 when MRNA reported 0.01B in revenue.
Any self directed investor doing their due diligence on MRNA or any other given stock can benefit from
researching all of the Moderna past earnings — and here, we present each quarter's result all together
on one page for easy comparison. Studying this information can help when projecting future earnings, as well
as determining whether the past earnings trajectory justifies the current stock value.
That's why we bring you PastEarnings
.com to make it easy for investors to investigate
Moderna past earnings, or the past earnings information for any stock in our coverage universe.
And in your continued research we hope you will be sure to check out the further links included for earnings
surprises history (beat/miss data) as well as next earnings dates for MRNA. Thanks for visiting, and the next
time you need to research MRNA past earnings
or those of another stock, we hope you'll think of our site, as your
go-to past earnings research resource of choice.